Questcor Pharmaceuticals (QCOR) 76.95 $QCOR
Questcor Partners with National Kidney Foundation as National Sponsor of Kidney Walk
PR Newswire - Thu Apr 17, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is partnering with the National Kidney Foundation (NKF) to become a National Sponsor of Kidney Walk, the country's largest walk to raise money and awareness for kidney disease.
Shares of QCOR Up 15.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:13AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 weeks, Questcor Pharmaceuticals has returned 15.74% as of today's recent price of $78.02.
Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:25PM CDT
Eli Lilly/ Boehringer new drug application (NDA) for their empagliflozin/Tradjenta (linagliptin) combination has been accepted for review by the FDA for type II diabetes.
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
QUESTCOR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Questcor Pharmaceuticals Inc. Over the Proposed Sale of the Company to Mallinckrodt plc
PR Newswire - Mon Apr 14, 6:45PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Questcor Pharmaceuticals Inc. ("Questcor" or the "Company"
(Nasdaq: QCOR) for potential breaches of fiduciary duties in connection with the sale of the Company to Mallinckrodt plc for approximately $5.2 billion. The Company's stockholders will receive $30.00 cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own.
Questcor Pharmaceuticals Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 3:54PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $77.40 to a high of $81.93. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $79.65 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:00AM CDT
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.
Acquisitions, Director Appointments, Collaborations, New Product Launches, and Earnings Guidance Revisions - Analyst Notes on Questcor, Regeneron, Lilly, Medtronic and Alexion
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Co. (NYSE: LLY), Medtronic Inc. (NYSE: MDT) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1084-100free.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:30AM CDT
Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%. One benefited from positive preliminary data from an early-stage clinical trial. Another surged...
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 7:00AM CDT
It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. ...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
INVESTOR ALERT - Questcor Pharmaceuticals, Inc.: The Law Offices of Vincent Wong Investigates the Sale of Questcor Pharmaceuticals, Inc. to Mallinckrodt
Business Wire - Fri Apr 11, 1:21PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc. (NasdaqGS:QCOR) ("Questcor" in connection with the sale of the Company to Mallinckrodt.
Lifshitz & Miller Law Firm Announces Investigation of Imperva, Inc., OBA Financial Services, Inc., Och-Ziff Capital Management Group LLC, Questcor Pharmaceuticals, Inc., Vocus, Inc. and Zygo Corporation
PR Newswire - Fri Apr 11, 11:30AM CDT
Imperva, Inc.
Questcor Pharmaceuticals (QCOR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:40AM CDT
Questcor Pharmaceuticals (QCOR) Shares March Higher, Can It Continue?
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Nektar Presents Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:10PM CDT
Nektar presented preclinical data on NKTR-102 and NKTR-214 at the AACR.
ImmunoGen Up on Positive Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:00PM CDT
ImmunoGen's shares have been up over a couple of trading sessions following positive pipeline results.
PolyOne, Anika, Methode Among The Leading Small Caps
at Investor's Business Daily - Thu Apr 10, 7:02AM CDT
The market is in correction but investors can still find stocks that are poised to post big gains during this earnings season. The season official kicked off Tuesday with Alcoa (AA) reporting late. Kapstone Paper & Packaging (KS), Anika Therapeutics...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Questcor Pharmaceuticals, Inc. In Connection With the Sale of The Company
Business Wire - Wed Apr 09, 5:15PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company" (Nasdaq: QCOR) relating to the proposed acquisition by Mallinckrodt plc ("Mallinckrodt" .
Questcor Partners with National Kidney Foundation as National Sponsor of Kidney Walk
PR Newswire - Thu Apr 17, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it is partnering with the National Kidney Foundation (NKF) to become a National Sponsor of Kidney Walk, the country's largest walk to raise money and awareness for kidney disease.
Shares of QCOR Up 15.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:13AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 weeks, Questcor Pharmaceuticals has returned 15.74% as of today's recent price of $78.02.
Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:25PM CDT
Eli Lilly/ Boehringer new drug application (NDA) for their empagliflozin/Tradjenta (linagliptin) combination has been accepted for review by the FDA for type II diabetes.
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
QUESTCOR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Questcor Pharmaceuticals Inc. Over the Proposed Sale of the Company to Mallinckrodt plc
PR Newswire - Mon Apr 14, 6:45PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Questcor Pharmaceuticals Inc. ("Questcor" or the "Company"
(Nasdaq: QCOR) for potential breaches of fiduciary duties in connection with the sale of the Company to Mallinckrodt plc for approximately $5.2 billion. The Company's stockholders will receive $30.00 cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own. Questcor Pharmaceuticals Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 3:54PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $77.40 to a high of $81.93. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $79.65 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:00AM CDT
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.
Acquisitions, Director Appointments, Collaborations, New Product Launches, and Earnings Guidance Revisions - Analyst Notes on Questcor, Regeneron, Lilly, Medtronic and Alexion
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Co. (NYSE: LLY), Medtronic Inc. (NYSE: MDT) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1084-100free.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:30AM CDT
Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%. One benefited from positive preliminary data from an early-stage clinical trial. Another surged...
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 7:00AM CDT
It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. ...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
INVESTOR ALERT - Questcor Pharmaceuticals, Inc.: The Law Offices of Vincent Wong Investigates the Sale of Questcor Pharmaceuticals, Inc. to Mallinckrodt
Business Wire - Fri Apr 11, 1:21PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc. (NasdaqGS:QCOR) ("Questcor"
in connection with the sale of the Company to Mallinckrodt. Lifshitz & Miller Law Firm Announces Investigation of Imperva, Inc., OBA Financial Services, Inc., Och-Ziff Capital Management Group LLC, Questcor Pharmaceuticals, Inc., Vocus, Inc. and Zygo Corporation
PR Newswire - Fri Apr 11, 11:30AM CDT
Imperva, Inc.
Questcor Pharmaceuticals (QCOR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:40AM CDT
Questcor Pharmaceuticals (QCOR) Shares March Higher, Can It Continue?
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Nektar Presents Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:10PM CDT
Nektar presented preclinical data on NKTR-102 and NKTR-214 at the AACR.
ImmunoGen Up on Positive Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:00PM CDT
ImmunoGen's shares have been up over a couple of trading sessions following positive pipeline results.
PolyOne, Anika, Methode Among The Leading Small Caps
at Investor's Business Daily - Thu Apr 10, 7:02AM CDT
The market is in correction but investors can still find stocks that are poised to post big gains during this earnings season. The season official kicked off Tuesday with Alcoa (AA) reporting late. Kapstone Paper & Packaging (KS), Anika Therapeutics...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Questcor Pharmaceuticals, Inc. In Connection With the Sale of The Company
Business Wire - Wed Apr 09, 5:15PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company"
(Nasdaq: QCOR) relating to the proposed acquisition by Mallinckrodt plc ("Mallinckrodt" . 
